Salivary gland cancer: an update on present and emerging therapies

Area of Science:

• Oncology
• Molecular Genetics
• Cancer Biology

Background:

• Malignant salivary gland tumors represent a small fraction of global cancers, exhibiting significant heterogeneity in histology, spread, and recurrence.
• Understanding this variability is crucial for tailoring treatment and improving patient outcomes.
• Recent advances in molecular genetics have identified a network of gene fusions in salivary gland carcinomas.

Purpose of the Study:

• To highlight the diagnostic and therapeutic potential of molecular genetic discoveries in salivary gland carcinomas.
• To review current treatment modalities including surgery, radiation, and chemotherapy.
• To emphasize the importance of understanding recurrence risk factors for treatment planning.

Main Methods:

• Review of recent molecular genetic studies identifying gene fusions in salivary gland carcinomas.
• Analysis of current therapeutic strategies: surgery, radiation therapy, and chemotherapy.
• Examination of the role of fusion oncoproteins in cellular processes.

Main Results:

• Gene fusions in salivary gland carcinomas encode oncoproteins involved in growth-factor signaling and cell-cycle regulation.
• These fusions offer potential for diagnosis and targeted therapy development.
• Surgery is primary for operable tumors; radiation is key postoperatively and for inoperable cases. Chemotherapy is increasingly used concurrently or palliatively.

Conclusions:

• Molecular discoveries, particularly gene fusions, are transforming the understanding and management of salivary gland carcinomas.
• Personalized treatment approaches integrating surgery, radiation, chemotherapy, and targeted agents are essential.
• Future research should focus on clinical trials for combined therapies and molecularly guided treatments.